Axsome Therapeutics Hits Milestone: FDA Approval of Auvelity for Alzheimer's Disease Agitation
On a recent conference call, Axsome Therapeutics reported strong year-over-year growth across its business in the first quarter of 2026. The company's commercial products and advancing research and development pipeline were key drivers behind this performance.
Total revenue from Axsome's three marketed products reached $191 million, representing a 57% increase over the same period last year. This growth was fueled by sales of Auvelity and Sunosi, with Symbravo also contributing to the company's strong commercial results.
The expansion of the sales force for Auvelity, along with plans to expand the sales force for Symbravo and increased covered lives and quality of coverage for all marketed products, will support continued revenue growth in the years to come. This development was highlighted by Dr. Herriot Tabuteau, Axsome's Chief Executive Officer.
In a major milestone, the FDA approved Auvelity for the treatment of agitation associated with Alzheimer's disease last week. This approval marks an important breakthrough for patients living with Alzheimer's disease and their families and caregivers. It also represents a significant achievement for Axsome, as it introduces a first-in-class treatment option for this debilitating condition.
The FDA granted Auvelity breakthrough therapy designation and priority review in this indication, and the approval is a testament to the company's research and development productivity. With this development, the commercial infrastructure supporting Auvelity has been augmented, providing Axsome with a clear line of sight to the market potential for this product.
Axsome's Chief Commercial Officer, Ari Maizel, will be providing an update on the peak sales estimate for the Auvelity franchise based on these developments. The company's industry-leading pipeline is advancing and expanding at a rapid pace, with a focus on developing first-in-class and best-in-class products.
On the regulatory front, Axsome has submitted its NDA for AXS-12 for the treatment of cataplexy and narcolepsy following the FDA approval of Auvelity. Clinically, ongoing trials are progressing, and phase III trials will be initiated within the next few months. The addition of AXS-20, a potentially first-in-class pre-phase III PDE10A inhibitor for schizophrenia and Tourette syndrome, further expands Axsome's pipeline.
With six product candidates targeting 10 different highly burdensome conditions in psychiatry and neurology, Axsome is advancing the commercialization of three differentiated marketed medicines across four highly prevalent indications. The company is well-positioned to realize robust growth driven by execution across its commercial portfolio for long-term Auvelity in Alzheimer's disease agitation and the advancement of the rest of its neuroscience pipeline.
